Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

HealthLynked (HLYK) EBIT Margin (2016 - 2025)

HealthLynked (HLYK) has disclosed EBIT Margin for 10 consecutive years, with 189.59% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin rose 9363.0% to 189.59% in Q3 2025 year-over-year; TTM through Sep 2025 was 130.56%, a 2125.0% increase, with the full-year FY2024 number at 155.49%, down 8294.0% from a year prior.
  • EBIT Margin was 189.59% for Q3 2025 at HealthLynked, down from 115.26% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 10.76% in Q3 2021 to a low of 3772.35% in Q4 2022.
  • A 5-year average of 304.22% and a median of 115.26% in 2025 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: tumbled -369991bps in 2022, then soared 365292bps in 2023.
  • HealthLynked's EBIT Margin stood at 72.44% in 2021, then tumbled by -5108bps to 3772.35% in 2022, then skyrocketed by 97bps to 119.43% in 2023, then decreased by -1bps to 120.98% in 2024, then plummeted by -57bps to 189.59% in 2025.
  • Per Business Quant, the three most recent readings for HLYK's EBIT Margin are 189.59% (Q3 2025), 115.26% (Q2 2025), and 120.3% (Q1 2025).